ONCOLOGY Vol 25 No 6 | Oncology

The IGF-1R Pathway as a Therapeutic Target

May 17, 2011

In this issue of ONCOLOGY, Golan and Javle present a timely review of the current status of the insulin growth factor-1 receptor (IGF-1R) signaling pathway as a therapeutic target, with a specific focus on gastrointestinal (GI) cancers.

When to Treat Myelodysplastic Syndromes

May 15, 2011

Myelodysplastic syndromes, also referred to collectively as MDS, have significant biological and clinical heterogeneity, a highly variable natural history, and a complex pathobiology that is not clearly understood.

Tricking or Treating Myelodysplastic Syndromes

May 13, 2011

The myelodysplastic syndromes (MDS) are a heterogeneous spectrum of clonal hematopoietic diseases characterized by bone marrow hypercellularity, dysplasia of cellular elements, and consequent inadequate hematopoiesis, with resultant peripheral blood cytopenias.

Myelodysplastic Syndromes: Where Do We Go From Here?

May 13, 2011

The review by Dr. Akhtari outlines the diagnosis, prognosis, and treatment options for patients with myelodysplastic syndromes (MDS), and touches on the current challenges in treating patients suffering from MDS.

Preventing Prostate Cancer Overdiagnosis From Becoming Overtreatment

May 12, 2011

The controversy surrounding PSA screening is one of the most heated in oncology. The potential benefits include prevention of prostate cancer morbidity and mortality, but the men potentially harmed through overdiagnosis and overtreatment outnumber those who benefit.

Aggressive Prostate Cancer: High Blood Levels of Omega-3s Doubled the Risk, but High Levels of Trans–Fatty Acids Cut Risk in Half

April 27, 2011

An analysis of data from 3,400 men in the large nationwide Prostate Cancer Prevention Trial indicates that, contrary to what might be expected, men with the highest blood percentages of DHA (docosahexaenoic acid), an omega-3 fatty acid commonly found in fatty fish, had 2.5 times the risk of developing aggressive, high-grade prostate cancer, compared with men who had the lowest levels.

First-in-Class Antimitotic Device Approved for Glioblastoma

April 21, 2011

The US Food and Drug Administration (FDA) has approved a portable noninvasive device, worn on the head, to treat adults whose glioblastoma multiforme (GBM) recurs or progresses following chemotherapy and radiation therapy.

Oncology Care in 2021: The FDA, Medicare, and Healthcare Reform

March 29, 2011

At the Association for Community Cancer Centers annual national meeting in Washington, DC this past March, the session on “Oncology Care in 2021” featured three panelists with significant experience in shaping healthcare policy.